Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14086 | 0.90 | SMN1; SMN2 (0.38) | EPHX2SMN1; SMN2PDGFRBKDRALDH1A1 | |
| SCHEMBL17354192 | 0.89 | KMT2A (0.45) | EPHX2KMT2ASIGMAR1 | |
| SCHEMBL17486582 | 0.85 | EPHX2 (0.38) | EPHX2SMN1; SMN2ALDH1A1SIGMAR1 | |
| SCHEMBL17486549 | 0.80 | ADRA1A (0.39) | EPHX2KMT2A | |
| SCHEMBL17486548 | 0.78 | EPHX2 (0.38) | EPHX2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17354470 | 0.77 | MAPT (0.39) | EPHX2PDGFRBKDR | |
| SCHEMBL17354347 | 0.75 | KMT2A (0.44) | EPHX2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL17486578 | 0.75 | CHRM3 (0.40) | EPHX2 | |
| SCHEMBL14268 | 0.75 | SIGMAR1 (0.37) | EPHX2SMN1; SMN2ALDH1A1SIGMAR1 | |
| SCHEMBL17354496 | 0.73 | SLC6A4 (0.43) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | EPHX2 3041/4885SMN1; SMN2 3979/4885PDGFRB 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.